fentanyl has been researched along with Cancer-Associated Pain in 87 studies
Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078)
fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rapid-acting fentanyl formulations are superior to oral morphine (OM) syrup in controlling breakthrough pain among patients with cancer, but they are expensive and unavailable in many countries." | 9.69 | Efficacy of reconstituted intravenous fentanyl to sublingual solution versus oral morphine syrup for breakthrough pain among patients with chronic gynecologic cancer pain: A randomized, double-blind, placebo-controlled trial. ( Thantiprechapong, T; Tilagul, T; Vasikasin, V, 2023) |
| "The purpose of this study was to evaluate the efficacy and safety of sublingual fentanyl in the treatment of breakthrough pain in cancer patients." | 9.41 | Efficacy, safety, and tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. ( Akbari, ME; Delshad, MH; Golmakani, E; Hashemi, M; Shadnoush, M; Zali, A, 2021) |
| "A low-dose fentanyl citrate patch was effective in the management of cancer pain in opioid-naïve patients and was well tolerated." | 9.34 | Efficacy and Safety of Fentanyl Citrate Patch, Including a Low-Dose 0.5 mg Formulation, in Opioid-Naïve Patients with Cancer Pain. ( Hashimoto, F; Okawa, K; Tanaka, Y; Terahara, T; Uchida, E; Yamaguchi, S, 2020) |
| "In this study, we could not demonstrate an effect of previous opioid exposure, from 20 to 120 mg oral morphine equivalent daily dose, on the absolute and relative efficacy and tolerability of 100 μg FST and 5 mg SCM for severe cancer pain episodes." | 9.30 | Effect of Opioid Exposure on Efficacy and Tolerability of Sublingual Fentanyl and Subcutaneous Morphine for Severe Cancer Pain Episodes. Secondary Analysis From a Double-Blind Double-Dummy, Randomized Trial. ( Brunelli, C; Caraceni, A; Centurioni, F; Kaasa, S; Manzoni, A; Pigni, A; Ricchini, F; Zecca, E, 2019) |
| "Fentanyl buccal soluble film (FBSF), a new formulation of fentanyl, is developed for the treatment of breakthrough pain (BTP) in opioid-tolerant patients with cancer." | 9.30 | A dose titration study of fentanyl buccal soluble film for breakthrough cancer pain in Taiwan. ( Chang, YF; Chao, TC; Chao, TY; Chiou, TJ; Huang, JS; Wang, CH, 2019) |
| "Purpose Fentanyl sublingual tablets (FST) are a potentially useful alternative to parenteral opioids such as subcutaneous morphine (SCM) to treat severe cancer pain episodes." | 9.24 | Fentanyl Sublingual Tablets Versus Subcutaneous Morphine for the Management of Severe Cancer Pain Episodes in Patients Receiving Opioid Treatment: A Double-Blind, Randomized, Noninferiority Trial. ( Brunelli, C; Caraceni, A; Centurioni, F; Manzoni, A; Pigni, A; Zecca, E, 2017) |
| "To investigate the relationship between effective fentanyl sublingual spray (FSS) doses for breakthrough cancer pain (BTCP) and around-the-clock (ATC) transdermal fentanyl patch (TFP)." | 9.22 | Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl. ( Alberts, DS; Parikh, N; Rauck, RL; Smith, CC, 2016) |
| "The current study assessed the long-term safety of fentanyl sublingual spray for managing breakthrough cancer pain (BTCP)." | 9.22 | Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain. ( Brownlow, RC; Bull, J; Minkowitz, H; Parikh, N; Rauck, R, 2016) |
| "Fentanyl products have shown superiority over oral opioids for the management of breakthrough cancer pain (BTcP)." | 9.22 | Fentanyl Pectin Nasal Spray Versus Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Comparative Study. ( Adile, C; Aielli, F; Casuccio, A; Costanzi, A; Mercadante, S, 2016) |
| " Only randomized controlled trials on the use of the transdermal fentanyl patch for the treatment of cancer pain were selected." | 8.98 | Transdermal fentanyl for cancer pain: Trial sequential analysis of 3406 patients from 35 randomized controlled trials. ( Ma, TT; Peng, CB; Wang, DD; Zhu, HD, 2018) |
| "After the CAVIDIOPAL study, we carried out an additional analysis to evaluate the impact of individualized management of breakthrough cancer pain, using the analgesic drug fentanyl, on quality of life (QoL) of advanced cancer patients receiving palliative care in Spain." | 8.12 | Low-dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain in palliative care. ( Abián, MH; Bermudo, CL; Canal-Sotelo, J; Casillas, IR; Mancilla, PG; Maradey, P; Rivero, SG; Rodríguez, AT; Viejo, MN, 2022) |
| "Serum fentanyl concentration and the safety and efficacy of once-a-day fentanyl citrate patch were investigated in pediatric and adolescent patients with cancer pain." | 8.02 | An Open-Label Study of the Pharmacokinetics and Tolerability of Once-a-Day Fentanyl Citrate Patch in Japanese Pediatric and Adolescent Patients with Cancer Pain. ( Hashimoto, F; Hiyama, E; Okawa, K; Otaka, K; Terahara, T; Yamaguchi, S, 2021) |
| "The aim of this paper was to assess the drug costs of the different biotechnologies (intranasal fentanyl spray (INFS), oral transmucosal fentanyl citrate (OTFC) and fentanyl buccal tablet (FBT)) in the treatment of breakthrough cancer pain (BTCP)." | 8.02 | The role of fentanyl in the treatment of breakthrough cancer pain: Different biotechnologies, different results and different drug costs. ( Bonetti, A; Fiorica, F; Franceschini, G; Giuliani, J; Sacchetto, A; Vaccari, F, 2021) |
| "The objective of this study was to evaluate the influence of cancer cachexia on pain control in cancer patients receiving a transdermal fentanyl patch (FP) and to investigate whether dry skin was a factor related to cancer cachexia and uncontrolled pain." | 7.96 | Cancer Cachexia May Hinder Pain Control When Using Fentanyl Patch. ( Chiba, T; Kimura, S; Kudo, K; Tairabune, T; Takahashi, H; Ueda, H, 2020) |
| "Sublingual fentanyl tablets (SFTs) have been shown to be a safe and effective option in controlling breakthrough cancer pain (BTcP)." | 7.91 | Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets. ( Coma, J; De Sanctis, V; Estivill, P; Ferreras, J; Folch, J; Fuentes, J; Guitart, J; Jiménez, AJ; Moya, J; Rodelas, F; Salazar, R; Sanz, A; Tomás, A; Vargas, MI, 2019) |
| "The aim of the study was to evaluate the effectiveness of fentanyl pectin nasal spray (FPNS) in controlling procedural breakthrough cancer pain (BTCP) in advanced cancer patients undergoing radiotherapy." | 7.91 | Effectiveness of fentanyl pectin nasal citrate in controlling episodes of breakthrough cancer pain triggered by routine radiotherapy procedures. ( Aymar, N; Jiménez, E; Mena, A; Mestre, F; Ortiz, I; Pardo, J; Roncero, R; Vidal, M, 2019) |
| "Fentanyl is an opioid commonly prescribed for cancer pain." | 7.88 | Analgesic effects of systemic fentanyl on cancer pain are mediated by not only central but also peripheral opioid receptors in mice. ( Andoh, T; Kuraishi, Y; Saiki, I; Shinohara, A, 2018) |
| "In 2013, oral transmucosal fentanyl was first approved in Japan for reducing breakthrough pain(BTP)." | 7.85 | [A New Therapeutic Approach for Cancer-Related Breakthrough Pain - Focused on Oral Transmucosal Fentanyl]. ( Hosonuma, R; Kaneshima, M; Kyosaka, B; Osato, S; Warita, E; Yomiya, K, 2017) |
| " Regarding adverse events, nausea occurred in 12." | 5.91 | Comparison of Analgesic Efficacy and Safety of Low-Dose Transdermal Fentanyl and Oral Oxycodone in Opioid-Naïve Patients with Cancer Pain. ( Fujimoto, H; Funato, M; Kawana, M; Kiribayashi, M; Kokubun, H; Kondo, M; Kusakabe, A; Miyasato, A; Nagatani, K; Nakamura, K; Ohno, R; Okamoto, K; Onoda, C; Ozeki, A; Suzuki, N, 2023) |
| "Rapid-acting fentanyl formulations are superior to oral morphine (OM) syrup in controlling breakthrough pain among patients with cancer, but they are expensive and unavailable in many countries." | 5.69 | Efficacy of reconstituted intravenous fentanyl to sublingual solution versus oral morphine syrup for breakthrough pain among patients with chronic gynecologic cancer pain: A randomized, double-blind, placebo-controlled trial. ( Thantiprechapong, T; Tilagul, T; Vasikasin, V, 2023) |
| "Cancer pain was observed in 131 of 160 patients with advanced cancer living at home." | 5.56 | [Analysis of Symptoms Relieved in Addition to Pain after Administration of Oxycodone or Morphine to Patients with Advanced Cancer Living at Home]. ( Watanabe, K, 2020) |
| "Adverse drug reactions were registered in 3%." | 5.48 | Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS. ( Gneist, M; Landthaler, R; Masel, EK; Watzke, HH, 2018) |
| "No published studies have looked at the dosing and use of rapid onset fentanyl preparations in children." | 5.46 | The use of rapid onset fentanyl in children and young people for breakthrough cancer pain. ( Anderson, AK; Burke, K; Coombes, L, 2017) |
| "Fentanyl has a strong first pass effect when administered orally and resorbed enterally, however it is well suited for transmucosal administration, e." | 5.46 | [Transmucosal fentanyl administration: sublingual, buccal, nasal - all the same? Treatment of breakthrough cancer pain]. ( Überall, MA, 2017) |
| "The pharmacokinetics of the sublingual fentanyl orally disintegrating tablet appear to be negatively affected by the presence of salivary gland hypofunction, although the moistening of the oral cavity before dosing results in a pharmacokinetic profile similar to that seen with the giving of pilocarpine hydrochloride." | 5.43 | The Influence of Low Salivary Flow Rates on the Absorption of a Sublingual Fentanyl Citrate Formulation for Breakthrough Cancer Pain. ( Buchanan, A; Davies, A; Mundin, G; Vriens, J; Waghorn, M; Webber, K, 2016) |
| " The absorption rate constant was 0." | 5.43 | Exposure to Fentanyl After Transdermal Patch Administration for Cancer Pain Management. ( Bista, SR; Hardy, J; Haywood, A; Hennig, S; Norris, R, 2016) |
| "The purpose of this study was to evaluate the efficacy and safety of sublingual fentanyl in the treatment of breakthrough pain in cancer patients." | 5.41 | Efficacy, safety, and tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. ( Akbari, ME; Delshad, MH; Golmakani, E; Hashemi, M; Shadnoush, M; Zali, A, 2021) |
| "A low-dose fentanyl citrate patch was effective in the management of cancer pain in opioid-naïve patients and was well tolerated." | 5.34 | Efficacy and Safety of Fentanyl Citrate Patch, Including a Low-Dose 0.5 mg Formulation, in Opioid-Naïve Patients with Cancer Pain. ( Hashimoto, F; Okawa, K; Tanaka, Y; Terahara, T; Uchida, E; Yamaguchi, S, 2020) |
| "Intranasal fentanyl (INF) quickly and noninvasively relieves severe pain, whereas intravenous hydromorphone (IVH) reliably treats severe cancer pain but requires vascular access." | 5.34 | Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: A randomized controlled trial. ( Banala, SR; Khattab, OK; Page, VD; Todd, KH; Warneke, CL; Yeung, SJ, 2020) |
| "Fentanyl buccal soluble film (FBSF), a new formulation of fentanyl, is developed for the treatment of breakthrough pain (BTP) in opioid-tolerant patients with cancer." | 5.30 | A dose titration study of fentanyl buccal soluble film for breakthrough cancer pain in Taiwan. ( Chang, YF; Chao, TC; Chao, TY; Chiou, TJ; Huang, JS; Wang, CH, 2019) |
| "In this study, we could not demonstrate an effect of previous opioid exposure, from 20 to 120 mg oral morphine equivalent daily dose, on the absolute and relative efficacy and tolerability of 100 μg FST and 5 mg SCM for severe cancer pain episodes." | 5.30 | Effect of Opioid Exposure on Efficacy and Tolerability of Sublingual Fentanyl and Subcutaneous Morphine for Severe Cancer Pain Episodes. Secondary Analysis From a Double-Blind Double-Dummy, Randomized Trial. ( Brunelli, C; Caraceni, A; Centurioni, F; Kaasa, S; Manzoni, A; Pigni, A; Ricchini, F; Zecca, E, 2019) |
| " This open-label, multicenter, noncomparative study aimed to assess the efficacy and safety of proportional doses of fentanyl buccal soluble film (FBSF) in patients with breakthrough cancer pain." | 5.27 | Proportional dose of rapid-onset opioid in breakthrough cancer pain management: An open-label, multicenter study. ( Chiang, WY; Chiou, JF; Hu, MH; Huang, MY; Lai, YL; Su, WH; Wu, SC; Yen, TY, 2018) |
| " In all patient groups, immediate-release oral morphine was the rescue analgesic and lactulose 10 mL twice daily was the prophylaxis of constipation; no antiemetics were used as prophylaxis." | 5.24 | A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients. ( Leppert, W; Nosek, H; Nosek, K; Onichimowski, D; Wordliczek, J, 2017) |
| "Purpose Fentanyl sublingual tablets (FST) are a potentially useful alternative to parenteral opioids such as subcutaneous morphine (SCM) to treat severe cancer pain episodes." | 5.24 | Fentanyl Sublingual Tablets Versus Subcutaneous Morphine for the Management of Severe Cancer Pain Episodes in Patients Receiving Opioid Treatment: A Double-Blind, Randomized, Noninferiority Trial. ( Brunelli, C; Caraceni, A; Centurioni, F; Manzoni, A; Pigni, A; Zecca, E, 2017) |
| "Fentanyl products have shown superiority over oral opioids for the management of breakthrough cancer pain (BTcP)." | 5.22 | Fentanyl Pectin Nasal Spray Versus Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Comparative Study. ( Adile, C; Aielli, F; Casuccio, A; Costanzi, A; Mercadante, S, 2016) |
| " The string was "rapid onset opioids" or "transmucosal fentanyl" and "breakthrough cancer pain"." | 5.22 | Bibliometric Network Analysis on Rapid-Onset Opioids for Breakthrough Cancer Pain Treatment. ( Armignacco, A; Carpenedo, R; Cascella, M; Chinè, E; Coluccia, S; Crispo, A; Cuomo, A; Cutugno, F; Forte, CA; Franceschini, G; Gennaro, PD; Migliaccio, L; Monaco, F; Natoli, S; Nocerino, D; Picerno, P; Tafuri, M; Tracey, MC; Vittori, A, 2022) |
| "Guidelines tend to consider morphine and morphine-like opioids comparable and interchangeable in the treatment of chronic cancer pain, but individual responses can vary." | 5.22 | Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV 'real life' trial on the variability of response to opioids. ( Apolone, G; Azzarello, G; Bandieri, E; Caraceni, A; Cavanna, L; Corli, O; Crispino, C; Di Gregorio, R; Dragani, TA; Floriani, I; Galli, F; Gamucci, T; Greco, MT; Iorno, V; Kaasa, S; Lipari, G; Luzzani, M; Montanari, M; Pacchioni, M; Pavesi, L; Reale, C; Roberto, A; Valenti, D, 2016) |
| "The current study assessed the long-term safety of fentanyl sublingual spray for managing breakthrough cancer pain (BTCP)." | 5.22 | Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain. ( Brownlow, RC; Bull, J; Minkowitz, H; Parikh, N; Rauck, R, 2016) |
| "To investigate the relationship between effective fentanyl sublingual spray (FSS) doses for breakthrough cancer pain (BTCP) and around-the-clock (ATC) transdermal fentanyl patch (TFP)." | 5.22 | Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl. ( Alberts, DS; Parikh, N; Rauck, RL; Smith, CC, 2016) |
| " Fentanyl is a lipophilic opioid commonly proposed for intranasal use among pediatric patients, but no studies have been conducted yet about intranasal use of other available opioids for management of pediatric cancer pain." | 5.01 | Intranasal therapy with opioids for children and adolescents with cancer: results from clinical studies. ( Attinà, G; Capozza, MA; Mastrangelo, S; Maurizi, P; Ruggiero, A; Triarico, S, 2019) |
| " Only randomized controlled trials on the use of the transdermal fentanyl patch for the treatment of cancer pain were selected." | 4.98 | Transdermal fentanyl for cancer pain: Trial sequential analysis of 3406 patients from 35 randomized controlled trials. ( Ma, TT; Peng, CB; Wang, DD; Zhu, HD, 2018) |
| " A group of experts nominated by the 3 French Societies involved in the treatment of cancer pain (AFSOS, SFAP, SFETD), established new guidelines ratios for morphine switching and/or changing of route of administration, in patients for whom either pain was not adequatly managed or adverse effects were unbearable." | 4.98 | [Opioid switch and change of route of administration in cancer patients treated by morphine]. ( Ammar, D; Baron, L; Chvetzoff, G; Collin, E; Delorme, C; Delorme, T; Faure, S; Filbet, M; Hubault, P; Jovenin, N; Krakowski, I; Magnet, M; Michenot, N; Minello, C; Poulain, P; Rostaing, S, 2018) |
| "After the CAVIDIOPAL study, we carried out an additional analysis to evaluate the impact of individualized management of breakthrough cancer pain, using the analgesic drug fentanyl, on quality of life (QoL) of advanced cancer patients receiving palliative care in Spain." | 4.12 | Low-dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain in palliative care. ( Abián, MH; Bermudo, CL; Canal-Sotelo, J; Casillas, IR; Mancilla, PG; Maradey, P; Rivero, SG; Rodríguez, AT; Viejo, MN, 2022) |
| "The aim of this paper was to assess the drug costs of the different biotechnologies (intranasal fentanyl spray (INFS), oral transmucosal fentanyl citrate (OTFC) and fentanyl buccal tablet (FBT)) in the treatment of breakthrough cancer pain (BTCP)." | 4.02 | The role of fentanyl in the treatment of breakthrough cancer pain: Different biotechnologies, different results and different drug costs. ( Bonetti, A; Fiorica, F; Franceschini, G; Giuliani, J; Sacchetto, A; Vaccari, F, 2021) |
| "Serum fentanyl concentration and the safety and efficacy of once-a-day fentanyl citrate patch were investigated in pediatric and adolescent patients with cancer pain." | 4.02 | An Open-Label Study of the Pharmacokinetics and Tolerability of Once-a-Day Fentanyl Citrate Patch in Japanese Pediatric and Adolescent Patients with Cancer Pain. ( Hashimoto, F; Hiyama, E; Okawa, K; Otaka, K; Terahara, T; Yamaguchi, S, 2021) |
| "Despite publicised advice and warnings, there are only scant data on the non-indicated prescription of rapid-onset preparations of fentanyl (ROF) in non-cancer pain (NCP)." | 4.02 | [Use of rapid-onset fentanyl preparations beyond indication : A random questionnaire survey among congress participants and pain physicians]. ( Cascella, M; Hofbauer, H; Kieselbach, K; Schenk, M; Wartenberg, HC; Wirz, S, 2021) |
| " The most common ER opioids prescribed were oxycodone (26%) and fentanyl (23%), and the most common noncancer pain diagnoses were back pain (65%) and arthritis (48%)." | 3.96 | Medical Use of Long-term Extended-release Opioid Analgesics in Commercially Insured Adults in the United States. ( Dasgupta, N; Jonsson Funk, M; Young, JC, 2020) |
| "Fentanyl buccal tablet (FBT), a potent opioid, was approved in Canada in 2013 for breakthrough pain in opioid-tolerant adult cancer patients." | 3.96 | Effectiveness of Risk Minimization Measures for Fentanyl Buccal Tablet (FENTORA) in Canada: A Mixed-Methods Evaluation Using Surveys, Medical Chart Records and Web Surveillance. ( Bergamasco, A; Castilloux, AM; Kaplan, S; Moride, Y; Sergerie, M, 2020) |
| "The objective of this study was to evaluate the influence of cancer cachexia on pain control in cancer patients receiving a transdermal fentanyl patch (FP) and to investigate whether dry skin was a factor related to cancer cachexia and uncontrolled pain." | 3.96 | Cancer Cachexia May Hinder Pain Control When Using Fentanyl Patch. ( Chiba, T; Kimura, S; Kudo, K; Tairabune, T; Takahashi, H; Ueda, H, 2020) |
| "The aim of the study was to evaluate the effectiveness of fentanyl pectin nasal spray (FPNS) in controlling procedural breakthrough cancer pain (BTCP) in advanced cancer patients undergoing radiotherapy." | 3.91 | Effectiveness of fentanyl pectin nasal citrate in controlling episodes of breakthrough cancer pain triggered by routine radiotherapy procedures. ( Aymar, N; Jiménez, E; Mena, A; Mestre, F; Ortiz, I; Pardo, J; Roncero, R; Vidal, M, 2019) |
| "Sublingual fentanyl tablets (SFTs) have been shown to be a safe and effective option in controlling breakthrough cancer pain (BTcP)." | 3.91 | Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets. ( Coma, J; De Sanctis, V; Estivill, P; Ferreras, J; Folch, J; Fuentes, J; Guitart, J; Jiménez, AJ; Moya, J; Rodelas, F; Salazar, R; Sanz, A; Tomás, A; Vargas, MI, 2019) |
| ", episode) crossover trials of fentanyl for breakthrough cancer pain illustrates the use of multiperiod crossover trials to examine heterogeneity of treatment response." | 3.91 | Demonstrating Heterogeneity of Treatment Effects Among Patients: An Overlooked but Important Step Toward Precision Medicine. ( Cai, X; Dworkin, RH; Farrar, JT; Gao, S; Gewandter, JS; He, H; Katz, NP; Markman, JD; McDermott, MP; Senn, S; Turk, DC, 2019) |
| " We describe the case of a patient suffering from breaktrough cancer pain treated with sublingual fentanyl." | 3.91 | [Breaktrough cancer pain in metastatic prostate adenocarcinoma: a case report.] ( Miolo, G; Santeufemia, DA, 2019) |
| "Transmucosal immediate-release fentanyls (TIRFs), indicated solely for breakthrough cancer pain in opioid-tolerant patients, are subject to a US Food and Drug Administration (FDA) Risk Evaluation and Mitigation Strategy (REMS) to prevent them from being prescribed inappropriately." | 3.91 | Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products. ( Alexander, GC; Heyward, J; Lurie, P; Olson, L; Rollman, JE; Sharfstein, J, 2019) |
| "Fentanyl is an opioid commonly prescribed for cancer pain." | 3.88 | Analgesic effects of systemic fentanyl on cancer pain are mediated by not only central but also peripheral opioid receptors in mice. ( Andoh, T; Kuraishi, Y; Saiki, I; Shinohara, A, 2018) |
| " Group 1 was consisted of 353 patients whose basal cancer pain of intensity 4-7 NRS was treated weak opiates (basal analgetic- fixed combination of tramadol/paracetamol (37." | 3.85 | Characteristics and Treatment of Breakthrought Pain (BTcP) in Palliative Care. ( Husic, S; Imamovic, S; Matic, S; Sukalo, A, 2017) |
| "In 2013, oral transmucosal fentanyl was first approved in Japan for reducing breakthrough pain(BTP)." | 3.85 | [A New Therapeutic Approach for Cancer-Related Breakthrough Pain - Focused on Oral Transmucosal Fentanyl]. ( Hosonuma, R; Kaneshima, M; Kyosaka, B; Osato, S; Warita, E; Yomiya, K, 2017) |
| "The incidence of delirium after the commencement of fentanyl injection was significantly lower, suggesting that fentanyl is a useful opioid injection drug from the perspective of delirium risk." | 3.85 | Incidence of Delirium Among Patients Having Cancer Injected With Different Opioids for the First Time. ( Ishikawa, H; Matsumoto, T; Mori, K; Omae, K; Osaka, I; Sato, T; Shino, M; Tanaka, R, 2017) |
| "The present study aimed to examine affecting factors for conversion ratio and to predict adequate fentanyl dose for patients with cancer pain in opioid switching from oral oxycodone." | 3.83 | Indication of Adequate Transdermal Fentanyl Dose in Opioid Switching From Oral Oxycodone in Patients With Cancer. ( Chisaki, Y; Fujihara, S; Matsumura, C; Takahashi, K; Yamada, M; Yano, Y, 2016) |
| "In this small study in palliative cancer patients under real-life clinical conditions, the influence of CYP3A on fentanyl variability was investigated." | 2.90 | Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients. ( Bardenheuer, HJ; Burhenne, J; Geist, MJP; Mikus, G; Skopp, G; Ziesenitz, VC, 2019) |
| "Morphine was associated with the less negative impact of pain on the ability to walk and normal work, and tendency on activity (BPI-SF) and lower consumption of rescue morphine." | 2.90 | Comparison of the Quality of Life of Cancer Patients with Pain Treated with Oral Controlled-Release Morphine and Oxycodone and Transdermal Buprenorphine and Fentanyl. ( Leppert, W; Nosek, K, 2019) |
| "Cancer pain is still inadequately treated in up to 60% of cancer patients." | 2.82 | Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer. ( Geurts, JW; Haumann, J; Joosten, EA; Kremer, B; van den Beuken-van Everdingen, MH; van Kuijk, SM, 2016) |
| "Treatment directed towards painful metastases must be considered." | 2.66 | Breakthrough cancer pain in 2020. ( Klepstad, P; Løhre, ET; Thronæs, M, 2020) |
| "Head and neck cancers (HNC) represent 5% of all malignancies worldwide with about 180,000 cancer deaths per year." | 2.66 | Is pain part of a systemic syndrome in head and neck cancer? ( Argenone, A; Bossi, P; Depenni, R; Ghiani, M, 2020) |
| "Failure to recognize the impact of various situations described throughout this work, including the bioavailability due to loss of oral route, due to pharmacokinetics and pharmacodynamics of the various drugs, either in the context of the impaired metabolism or excretion, or in due to pharmacological interactions, conditions a serious risk of subtreatment of pain and consequent impact in terms of quality of life." | 2.61 | [Opioids for Cancer Pain and its Use under Particular Conditions: A Narrative Review]. ( Brás, M; Fragoso, M; Vieira, C, 2019) |
| " Five studies and guidelines also suggest that oral opioids (not including TIRF products) be dosed proportionally to baseline opioids at 10%-20% of the 24-hour, around-the-clock dose." | 2.55 | Breakthrough Cancer Pain: A Systematic Review of Pharmacologic Management . ( Brant, JM; Gallagher, E; Rodgers, BB; Sundaramurthi, T, 2017) |
| "Fentanyl is a strong opioid that is available for various administration routes, and which is widely used to treat cancer-related pain." | 2.55 | A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients. ( Koolen, SL; Kuip, EJ; Mathijssen, RH; van der Rijt, CC; Zandvliet, ML, 2017) |
| "Cancer pain is a significant issue in terminally ill cancer patients (TICPs)." | 1.91 | Differences in Fentanyl Requirements in Terminally Ill Cancer Patients. ( Fujiwara, N; Ishiki, H; Nojima, M; Shimada, N; Tojo, A; Watanabe, A, 2023) |
| " Regarding adverse events, nausea occurred in 12." | 1.91 | Comparison of Analgesic Efficacy and Safety of Low-Dose Transdermal Fentanyl and Oral Oxycodone in Opioid-Naïve Patients with Cancer Pain. ( Fujimoto, H; Funato, M; Kawana, M; Kiribayashi, M; Kokubun, H; Kondo, M; Kusakabe, A; Miyasato, A; Nagatani, K; Nakamura, K; Ohno, R; Okamoto, K; Onoda, C; Ozeki, A; Suzuki, N, 2023) |
| "Although opioids have been shown to be effective for cancer pain, opioid-induced adverse events (AEs) are common." | 1.91 | Prevalence of opioid-induced adverse events across opioids commonly used for analgesic treatment in Japan: a multicenter prospective longitudinal study. ( Arakawa, S; Chiu, SW; Hiratsuka, Y; Hirayama, H; Inoue, A; Ishiki, H; Kosugi, K; Kubo, E; Matsuda, Y; Miyashita, M; Morita, T; Natsume, M; Nishijima, K; Ouchi, K; Sato, M; Satomi, E; Shigeno, T; Shimizu, M; Shimoda, M; Shimoi, T; Tagami, K; Yamaguchi, T; Yokomichi, N, 2023) |
| "150 patients with liver cancer were divided into group A (transdermal fentanyl patch), group B (ERAS), and group C (transdermal fentanyl patch combined with ERAS)." | 1.72 | Effect of Transdermal Fentanyl Patch Combined with Enhanced Recovery after Surgery on the Curative Effect and Analgesic Effect of Liver Cancer. ( Fang, S; Lu, G; Xiao, H; Zhu, H, 2022) |
| "Cancer pain was observed in 131 of 160 patients with advanced cancer living at home." | 1.56 | [Analysis of Symptoms Relieved in Addition to Pain after Administration of Oxycodone or Morphine to Patients with Advanced Cancer Living at Home]. ( Watanabe, K, 2020) |
| " A strong consensus was achieved regarding which pharmacological treatment (transmucosal fentanyl) and dosing method (start low and go slow) are the most suitable for the older population." | 1.51 | Expert consensus on the management of breakthrough cancer pain in older patients. A Delphi study. ( Alarcón, MDL; Cabezón-Gutiérrez, L; Estévez, FV; Jiménez-López, AJ; Martín-Arroyo, JMT; Padrós, MC; Rebollo, MA; Sanz-Yagüe, A, 2019) |
| " TIRF use was mainly related to background opioid dosage and the patient's self-sufficiency in taking medication." | 1.48 | Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer. ( Calvieri, A; Casale, G; Dardeli, A; Eusepi, G; Giannarelli, D; Magnani, C; Mastroianni, C; Restuccia, MR, 2018) |
| "Adverse drug reactions were registered in 3%." | 1.48 | Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS. ( Gneist, M; Landthaler, R; Masel, EK; Watzke, HH, 2018) |
| "No published studies have looked at the dosing and use of rapid onset fentanyl preparations in children." | 1.46 | The use of rapid onset fentanyl in children and young people for breakthrough cancer pain. ( Anderson, AK; Burke, K; Coombes, L, 2017) |
| "Fentanyl has a strong first pass effect when administered orally and resorbed enterally, however it is well suited for transmucosal administration, e." | 1.46 | [Transmucosal fentanyl administration: sublingual, buccal, nasal - all the same? Treatment of breakthrough cancer pain]. ( Überall, MA, 2017) |
| " This study investigated the patterns of opioid prescribing and characterized the dosing and duration of opioid use in patients with noncancer and cancer pain." | 1.46 | Dose and Duration of Opioid Use in Patients with Cancer and Noncancer Pain at an Outpatient Hospital Setting in Malaysia. ( Choy, LW; Ismail, CR; Rahman, NA; Zin, CS, 2017) |
| " The absorption rate constant was 0." | 1.43 | Exposure to Fentanyl After Transdermal Patch Administration for Cancer Pain Management. ( Bista, SR; Hardy, J; Haywood, A; Hennig, S; Norris, R, 2016) |
| "The pharmacokinetics of the sublingual fentanyl orally disintegrating tablet appear to be negatively affected by the presence of salivary gland hypofunction, although the moistening of the oral cavity before dosing results in a pharmacokinetic profile similar to that seen with the giving of pilocarpine hydrochloride." | 1.43 | The Influence of Low Salivary Flow Rates on the Absorption of a Sublingual Fentanyl Citrate Formulation for Breakthrough Cancer Pain. ( Buchanan, A; Davies, A; Mundin, G; Vriens, J; Waghorn, M; Webber, K, 2016) |
| " A population pharmacokinetic model was developed and evaluated using non-linear mixed-effects modelling." | 1.43 | Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients. ( Abrantes, JA; de Bruijn, P; Falcão, A; Jönsson, S; Kuip, EJ; Mathijssen, RH; Oosten, AW; van der Rijt, CC, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 62 (71.26) | 24.3611 |
| 2020's | 25 (28.74) | 2.80 |
| Authors | Studies |
|---|---|
| Takemura, M | 1 |
| Niki, K | 1 |
| Okamoto, Y | 1 |
| Matsuda, Y | 2 |
| Omae, T | 1 |
| Takagi, T | 1 |
| Ueda, M | 1 |
| Hiyama, E | 1 |
| Yamaguchi, S | 2 |
| Okawa, K | 2 |
| Hashimoto, F | 2 |
| Otaka, K | 1 |
| Terahara, T | 2 |
| Rodríguez, AT | 1 |
| Viejo, MN | 1 |
| Maradey, P | 1 |
| Canal-Sotelo, J | 1 |
| Mancilla, PG | 1 |
| Rivero, SG | 1 |
| Casillas, IR | 1 |
| Abián, MH | 1 |
| Bermudo, CL | 1 |
| Cascella, M | 2 |
| Monaco, F | 1 |
| Nocerino, D | 1 |
| Chinè, E | 1 |
| Carpenedo, R | 1 |
| Picerno, P | 1 |
| Migliaccio, L | 1 |
| Armignacco, A | 1 |
| Franceschini, G | 2 |
| Coluccia, S | 1 |
| Gennaro, PD | 1 |
| Tracey, MC | 1 |
| Forte, CA | 1 |
| Tafuri, M | 1 |
| Crispo, A | 1 |
| Cutugno, F | 1 |
| Vittori, A | 1 |
| Natoli, S | 1 |
| Cuomo, A | 1 |
| Yomiya, K | 2 |
| Zhu, H | 1 |
| Xiao, H | 1 |
| Lu, G | 1 |
| Fang, S | 1 |
| Watanabe, A | 2 |
| Shimada, N | 2 |
| Ishiki, H | 3 |
| Fujiwara, N | 2 |
| Nojima, M | 2 |
| Tojo, A | 2 |
| Mercadante, S | 6 |
| Begley, EK | 1 |
| Poole, HM | 1 |
| Sumnall, HR | 1 |
| Frank, BF | 1 |
| Montgomery, C | 1 |
| Thantiprechapong, T | 1 |
| Tilagul, T | 1 |
| Vasikasin, V | 1 |
| Kawana, M | 1 |
| Miyasato, A | 1 |
| Funato, M | 1 |
| Nagatani, K | 1 |
| Suzuki, N | 1 |
| Onoda, C | 1 |
| Fujimoto, H | 1 |
| Ohno, R | 1 |
| Kusakabe, A | 1 |
| Kiribayashi, M | 1 |
| Nakamura, K | 1 |
| Kondo, M | 1 |
| Ozeki, A | 1 |
| Okamoto, K | 1 |
| Kokubun, H | 1 |
| Hiratsuka, Y | 1 |
| Tagami, K | 1 |
| Inoue, A | 1 |
| Sato, M | 1 |
| Kosugi, K | 1 |
| Kubo, E | 1 |
| Natsume, M | 1 |
| Arakawa, S | 1 |
| Shimizu, M | 1 |
| Yokomichi, N | 1 |
| Chiu, SW | 1 |
| Shimoda, M | 1 |
| Hirayama, H | 1 |
| Nishijima, K | 1 |
| Ouchi, K | 1 |
| Shimoi, T | 1 |
| Shigeno, T | 1 |
| Yamaguchi, T | 1 |
| Miyashita, M | 1 |
| Morita, T | 1 |
| Satomi, E | 1 |
| Moryl, N | 1 |
| Bokhari, A | 1 |
| Griffo, Y | 1 |
| Hadler, R | 1 |
| Koranteng, L | 1 |
| Filkins, A | 1 |
| Zheng, T | 1 |
| Horn, SD | 1 |
| Inturrisi, CE | 1 |
| Morikawa, N | 1 |
| Kasahara, Y | 1 |
| Takahashi, Y | 1 |
| Nishikura, K | 1 |
| Nishihara, M | 1 |
| Geist, MJP | 1 |
| Ziesenitz, VC | 1 |
| Bardenheuer, HJ | 1 |
| Burhenne, J | 1 |
| Skopp, G | 1 |
| Mikus, G | 1 |
| Kaplan, S | 1 |
| Bergamasco, A | 1 |
| Sergerie, M | 1 |
| Castilloux, AM | 1 |
| Moride, Y | 1 |
| Bossi, P | 1 |
| Ghiani, M | 1 |
| Argenone, A | 1 |
| Depenni, R | 1 |
| Camps Herrero, C | 1 |
| Batista, N | 1 |
| Díaz Fernández, N | 1 |
| Escobar Álvarez, Y | 1 |
| Gonzalo Gómez, A | 1 |
| Isla Casado, D | 1 |
| Salud, A | 1 |
| Terrasa Pons, J | 1 |
| Guillem Porta, V | 1 |
| Løhre, ET | 1 |
| Thronæs, M | 1 |
| Klepstad, P | 1 |
| Chiba, T | 1 |
| Takahashi, H | 1 |
| Tairabune, T | 1 |
| Kimura, S | 1 |
| Ueda, H | 1 |
| Kudo, K | 1 |
| Watanabe, K | 1 |
| Banala, SR | 1 |
| Khattab, OK | 1 |
| Page, VD | 1 |
| Warneke, CL | 1 |
| Todd, KH | 1 |
| Yeung, SJ | 1 |
| Chiou, TJ | 1 |
| Chao, TC | 1 |
| Chao, TY | 1 |
| Huang, JS | 1 |
| Chang, YF | 1 |
| Wang, CH | 1 |
| Uchida, E | 1 |
| Tanaka, Y | 1 |
| Wirz, S | 1 |
| Schenk, M | 1 |
| Hofbauer, H | 1 |
| Wartenberg, HC | 1 |
| Kieselbach, K | 1 |
| Baamonde, A | 1 |
| Menéndez, L | 1 |
| González-Rodríguez, S | 1 |
| Lastra, A | 1 |
| Seitz, V | 1 |
| Stein, C | 1 |
| Machelska, H | 1 |
| Giuliani, J | 1 |
| Fiorica, F | 1 |
| Sacchetto, A | 1 |
| Vaccari, F | 1 |
| Bonetti, A | 1 |
| Hashemi, M | 1 |
| Zali, A | 1 |
| Golmakani, E | 1 |
| Delshad, MH | 1 |
| Shadnoush, M | 1 |
| Akbari, ME | 1 |
| Koolen, SL | 2 |
| Van der Rijt, CC | 3 |
| Kaneshima, M | 1 |
| Kyosaka, B | 1 |
| Warita, E | 1 |
| Hosonuma, R | 1 |
| Osato, S | 1 |
| Brant, JM | 1 |
| Rodgers, BB | 1 |
| Gallagher, E | 1 |
| Sundaramurthi, T | 1 |
| Cortesi, PA | 2 |
| D'Angiolella, LS | 1 |
| Vellucci, R | 2 |
| Allegri, M | 1 |
| Casale, G | 2 |
| Favaretti, C | 1 |
| Kheiraoui, F | 1 |
| Cesana, G | 1 |
| Mantovani, LG | 1 |
| Wiffen, PJ | 1 |
| Wee, B | 1 |
| Derry, S | 1 |
| Bell, RF | 1 |
| Moore, RA | 1 |
| Guitart, J | 2 |
| Vargas, MI | 2 |
| De Sanctis, V | 2 |
| Folch, J | 2 |
| Salazar, R | 2 |
| Fuentes, J | 2 |
| Coma, J | 2 |
| Ferreras, J | 2 |
| Moya, J | 2 |
| Tomás, A | 2 |
| Estivill, P | 2 |
| Rodelas, F | 2 |
| Jiménez, AJ | 2 |
| Sanz, A | 2 |
| Masel, EK | 1 |
| Landthaler, R | 1 |
| Gneist, M | 1 |
| Watzke, HH | 1 |
| Breivik, H | 1 |
| Nosek, K | 2 |
| Leppert, W | 2 |
| Nosek, H | 1 |
| Wordliczek, J | 1 |
| Onichimowski, D | 1 |
| Husic, S | 1 |
| Imamovic, S | 1 |
| Matic, S | 1 |
| Sukalo, A | 1 |
| de Bruijn, P | 3 |
| Kuip, EJM | 2 |
| Lam, MH | 1 |
| Mathijssen, RHJ | 2 |
| Koolen, SLW | 2 |
| Coombes, L | 1 |
| Burke, K | 1 |
| Anderson, AK | 1 |
| Überall, MA | 1 |
| Schuster, M | 1 |
| Bayer, O | 1 |
| Heid, F | 1 |
| Laufenberg-Feldmann, R | 1 |
| Wang, DD | 1 |
| Ma, TT | 1 |
| Zhu, HD | 1 |
| Peng, CB | 1 |
| Oldenmenger, WH | 1 |
| Thijs-Visser, MF | 1 |
| Oosten, AW | 2 |
| Oomen-de Hoop, E | 1 |
| Van der Rijt, CCD | 2 |
| Shinohara, A | 1 |
| Andoh, T | 1 |
| Saiki, I | 1 |
| Kuraishi, Y | 1 |
| Lux, EA | 1 |
| Schwittay, A | 1 |
| Kleeberg, UR | 1 |
| Papke, J | 1 |
| Yen, TY | 1 |
| Chiou, JF | 1 |
| Chiang, WY | 1 |
| Su, WH | 1 |
| Huang, MY | 1 |
| Hu, MH | 1 |
| Wu, SC | 1 |
| Lai, YL | 1 |
| Michenot, N | 1 |
| Rostaing, S | 1 |
| Baron, L | 1 |
| Faure, S | 1 |
| Jovenin, N | 1 |
| Hubault, P | 1 |
| Delorme, T | 1 |
| Collin, E | 1 |
| Filbet, M | 1 |
| Chvetzoff, G | 1 |
| Delorme, C | 1 |
| Minello, C | 1 |
| Magnet, M | 1 |
| Ammar, D | 1 |
| Krakowski, I | 1 |
| Poulain, P | 1 |
| Magnani, C | 1 |
| Giannarelli, D | 1 |
| Calvieri, A | 1 |
| Dardeli, A | 1 |
| Eusepi, G | 1 |
| Restuccia, MR | 1 |
| Mastroianni, C | 1 |
| Haumann, J | 2 |
| van Kuijk, SMJ | 1 |
| Joosten, EA | 2 |
| van den Beuken-van Everdingen, MHJ | 1 |
| Adile, C | 2 |
| Masedu, F | 2 |
| Marchetti, P | 1 |
| Costanzi, A | 2 |
| Aielli, F | 3 |
| Bechakra, M | 1 |
| Moerdijk, F | 1 |
| van Rosmalen, J | 1 |
| Koch, BCP | 1 |
| Sillevis Smitt, PAE | 1 |
| Jongen, JLM | 1 |
| Gunnellini, M | 1 |
| Gewandter, JS | 1 |
| McDermott, MP | 1 |
| He, H | 1 |
| Gao, S | 1 |
| Cai, X | 1 |
| Farrar, JT | 1 |
| Katz, NP | 1 |
| Markman, JD | 1 |
| Senn, S | 1 |
| Turk, DC | 1 |
| Dworkin, RH | 1 |
| Rollman, JE | 1 |
| Heyward, J | 1 |
| Olson, L | 1 |
| Lurie, P | 1 |
| Sharfstein, J | 1 |
| Alexander, GC | 1 |
| Santeufemia, DA | 1 |
| Miolo, G | 1 |
| Alarcón, MDL | 1 |
| Estévez, FV | 1 |
| Cabezón-Gutiérrez, L | 1 |
| Padrós, MC | 1 |
| Martín-Arroyo, JMT | 1 |
| Rebollo, MA | 1 |
| Jiménez-López, AJ | 1 |
| Sanz-Yagüe, A | 1 |
| Pardo, J | 1 |
| Mena, A | 1 |
| Jiménez, E | 1 |
| Aymar, N | 1 |
| Ortiz, I | 1 |
| Roncero, R | 1 |
| Mestre, F | 1 |
| Vidal, M | 1 |
| Triarico, S | 1 |
| Capozza, MA | 1 |
| Mastrangelo, S | 1 |
| Attinà, G | 1 |
| Maurizi, P | 1 |
| Ruggiero, A | 1 |
| Vieira, C | 1 |
| Brás, M | 1 |
| Fragoso, M | 1 |
| Ricchini, F | 1 |
| Caraceni, A | 3 |
| Zecca, E | 2 |
| Pigni, A | 2 |
| Centurioni, F | 2 |
| Manzoni, A | 2 |
| Kaasa, S | 2 |
| Brunelli, C | 2 |
| Arthur, JA | 1 |
| Reddy, A | 2 |
| Smith, U | 1 |
| Hui, D | 1 |
| Park, M | 1 |
| Liu, D | 2 |
| Vaughan-Adams, N | 1 |
| Haider, A | 1 |
| Williams, J | 1 |
| Bruera, E | 2 |
| Young, JC | 1 |
| Jonsson Funk, M | 1 |
| Dasgupta, N | 1 |
| Valenti, M | 1 |
| Matsumura, C | 1 |
| Yamada, M | 1 |
| Fujihara, S | 1 |
| Chisaki, Y | 1 |
| Takahashi, K | 1 |
| Yano, Y | 1 |
| Bista, SR | 1 |
| Haywood, A | 1 |
| Hardy, J | 1 |
| Norris, R | 1 |
| Hennig, S | 1 |
| Davies, A | 1 |
| Mundin, G | 1 |
| Vriens, J | 1 |
| Webber, K | 1 |
| Buchanan, A | 1 |
| Waghorn, M | 1 |
| Abrantes, JA | 1 |
| Jönsson, S | 1 |
| Kuip, EJ | 2 |
| Falcão, A | 1 |
| Mathijssen, RH | 2 |
| Minkowitz, H | 1 |
| Bull, J | 1 |
| Brownlow, RC | 1 |
| Parikh, N | 2 |
| Rauck, R | 1 |
| Yennurajalingam, S | 1 |
| Reddy, S | 1 |
| Wu, J | 1 |
| Dev, R | 1 |
| Corli, O | 1 |
| Floriani, I | 1 |
| Roberto, A | 1 |
| Montanari, M | 1 |
| Galli, F | 1 |
| Greco, MT | 1 |
| Dragani, TA | 1 |
| Azzarello, G | 1 |
| Luzzani, M | 1 |
| Cavanna, L | 1 |
| Bandieri, E | 1 |
| Gamucci, T | 1 |
| Lipari, G | 1 |
| Di Gregorio, R | 1 |
| Valenti, D | 1 |
| Reale, C | 1 |
| Pavesi, L | 1 |
| Iorno, V | 1 |
| Crispino, C | 1 |
| Pacchioni, M | 1 |
| Apolone, G | 1 |
| Alberts, DS | 1 |
| Smith, CC | 1 |
| Rauck, RL | 1 |
| Meijler, WJ | 1 |
| Tanaka, R | 1 |
| Ishikawa, H | 1 |
| Sato, T | 1 |
| Shino, M | 1 |
| Matsumoto, T | 1 |
| Mori, K | 1 |
| Omae, K | 1 |
| Osaka, I | 1 |
| Mücke, M | 1 |
| Conrad, R | 1 |
| Marinova, M | 1 |
| Cuhls, H | 1 |
| Elsner, F | 1 |
| Rolke, R | 1 |
| Radbruch, L | 1 |
| Casuccio, A | 1 |
| Ishida, T | 1 |
| Naito, T | 1 |
| Sato, H | 1 |
| Kawakami, J | 1 |
| Fanelli, G | 1 |
| Pannuti, R | 1 |
| Peruselli, C | 1 |
| Romualdi, P | 1 |
| Geurts, JW | 1 |
| van Kuijk, SM | 1 |
| Kremer, B | 1 |
| van den Beuken-van Everdingen, MH | 1 |
| Zandvliet, ML | 1 |
| Zin, CS | 1 |
| Rahman, NA | 1 |
| Ismail, CR | 1 |
| Choy, LW | 1 |
| Dyer, O | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Quality of Life Study in Patients With Cancer Breakthrough Pain Treated in Palliative Care Units[NCT02840500] | 101 participants (Actual) | Observational | 2016-06-27 | Completed | |||
| A Randomized Trial to Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain in Cancer Patients in the Emergency Department Setting[NCT02459964] | Phase 4 | 84 participants (Actual) | Interventional | 2015-09-14 | Completed | ||
| Fentanyl Buccal Soluble Films Feasible Dose Range Study for Breakthrough Pain in Taiwanese Cancer Patients[NCT03669263] | 36 participants (Actual) | Interventional | 2014-11-25 | Completed | |||
| An Observational Study to Assess the Efficacy, Safety, and Tolerability of Abstral Oral Disintegrating Tablet (ODT) for the Management of Breakthrough Cancer Pain in Korean Cancer Patients[NCT03895762] | 143 participants (Actual) | Observational | 2017-07-04 | Completed | |||
| RCT Comparing the Analgesic Efficacy of 4 Therapeutic Strategies Based on 4 Different Major Opioids (Fentanyl, Oxycodone, Buprenorphine vs Morphine) in Cancer Patients With Moderate/Severe Pain, at the Moment of Starting 3rd Step of WHO Analgesic Ladder.[NCT01809106] | Phase 4 | 518 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain[NCT00538850] | Phase 3 | 130 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Methadone for 'Adenocarcinopathic' Pain Treatment: Methadone vs. Morphine Vanguard RCT[NCT05325164] | Phase 3 | 0 participants (Actual) | Interventional | 2022-09-30 | Withdrawn (stopped due to Trial not started; change in Sponsor and Principal Investigator, trial to be registered again by new Sponsor/Investigator if it is started.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The median change in Numeric Rating Scale (NRS) pain intensity scores (assessed on an 11-point Likert scale with 0 = no pain and 10 = worst pain) from randomization, estimate of treatment initiation, to one hour post-treatment calculated for both treatment arms. (NCT02459964)
Timeframe: Baseline, One hour post time of drug delivery/treatment initiation
| Intervention | NRS Pain Intensity Score (Median) |
|---|---|
| Treatment Arm 1 (Intranasal Fentanyl) | 5.14 |
| Treatment Arm 2 (Intravenous Hydromorphone) | 4.90 |
Change in NRS pain intensity scores from randomization to one hour after treatment start based on the percentage of participants with severe pain, NRS score = 7-10, one hour after treatment start for both treatment arms. Numeric Rating Scale (NRS) pain intensity scores (assessed on an 11-point Likert scale with 0 = no pain and 10 = worst pain). (NCT02459964)
Timeframe: One (1) hour after treatment start.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm 1 (Intranasal Fentanyl) | 5 |
| Treatment Arm 2 (Intravenous Hydromorphone) | 10 |
Evaluation of the proportion of subjects who report full analgesia (full responders: FR). FR is operationally defined as a patient with a P.I.D. =/> 30% from visit 6 and visit 1 (NRS 0 to 10). (NCT01809106)
Timeframe: 28 days
| Intervention | participants (Number) |
|---|---|
| Morphine | 89 |
| Oxycodone | 90 |
| Buprenorphine | 95 |
| Fentanyl | 88 |
"Evaluation of the proportion of Non-Responder (NR) participants. NR correspond to the subjects who do not report any analgesic effects, with a P.I.D. (pain intensity difference) from visit 6 and visit 1 =/< 0%, (using a 0-10 NRS ). It includes the situations of average pain intensity stable or worsened at day 28 compared with baseline values." (NCT01809106)
Timeframe: 28 days
| Intervention | participants (Number) |
|---|---|
| Morphine | 14 |
| Oxycodone | 18 |
| Buprenorphine | 14 |
| Fentanyl | 11 |
The proportion of subjects with an increase of opioid daily dose > 5% compared with the basal dosage (OEI%). (NCT01809106)
Timeframe: 28 days
| Intervention | participants (Number) |
|---|---|
| Morphine | 13 |
| Oxycodone | 24 |
| Buprenorphine | 18 |
| Fentanyl | 45 |
"Pain intensity was assessed by the participant using a 0-100 mm visual analog scale where 0 represented no pain and 100 represented worst possible pain at 0 (baseline, beginning of the pain episode), 5, 10, 15, and 30 minutes after each dose of study medication during each breakthrough pain episode. The pain intensity difference was defined as the difference in pain intensity at the various time points versus time 0 (baseline). SPID30 was calculated as the time-weighted sum of the PID scores using the following formula: SPID30=(5*PID5)+(5*PID10)+(5*PID15)+(15*PID30). The minimum and maximum SPID30 scores were -3000 and 3000. A higher score indicates less pain." (NCT00538850)
Timeframe: Baseline (time 0, beginning of each pain episode) through 30 minutes after dosing for each pain episode
| Intervention | Units on a scale (Mean) |
|---|---|
| Fentanyl Sublingual Spray | 640.3 |
| Placebo | 399.6 |
Global evaluation of the study medication was assessed by the participant on a 5-point scale (1=Poor, 2=Fair, 3=Good, 4=Very good, 5=Excellent) at 30 and 60 minutes after each dose of study medication during each breakthrough pain episode. A higher score indicates a better evaluation. (NCT00538850)
Timeframe: 30 through 60 minutes after dosing for each pain episode
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| 30 minutes | 60 minutes | |
| Fentanyl Sublingual Spray | 2.8 | 3.1 |
| Placebo | 2.0 | 2.2 |
"Pain intensity was assessed by the participant using a 0-100 mm visual analog scale where 0 represented no pain and 100 represented worst possible pain at 0 (baseline, beginning of the pain episode), 5, 10, 15, 30, 45 and 60 minutes after each dose of study medication during each breakthrough pain episode. The pain intensity difference was defined as the difference in pain intensity at the various time points versus time 0 (baseline). SPID was calculated as the time-weighted sum of the PID scores using the following formulas: SPID5=(5*PID5), SPID10=(5*PID5)+(5*PID10), SPID15=(5*PID5)+(5*PID10)+(5*PID15), SPID30=(5*PID5)+(5*PID10)+(5*PID15)+(15*PID30), SPID45=(5*PID5)+(5*PID10)+(5*PID15)+(15*PID30)+(15*PID45), SPID60=(5*PID5)+(5*PID10)+(5*PID15)+(15*PID30) +(15*PID45) +(15*PID60). The minimum and maximum SPID scores were -500 to 500, -1000 to 1000, -1500 to 1500, -3000 to 3000, -4500 to 4500, and -6000 to 6000, respectively. A higher score indicates less pain." (NCT00538850)
Timeframe: Baseline (time 0, beginning of each pain episode) through 60 minutes after dosing for each pain episode
| Intervention | Units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| SPID5 | SPID10 | SPID15 | SPID45 | SPID60 | |
| Fentanyl Sublingual Spray | 40.3 | 115.0 | 220.6 | 1122.0 | 1649.0 |
| Placebo | 32.0 | 81.1 | 150.3 | 667.0 | 965.7 |
Pain relief (PAR) was assessed by the participant on a 5-point scale (1=No relief, 2=A little relief, 3=Moderate relief, 4=A lot of relief, 5=Complete relief) at 5, 10, 15, 30, 45 and 60 minutes after each dose of study medication during each breakthrough pain episode. TOTPAR was calculated as the time-weighted sum of the PAR scores at each time point using the following formulas: TOTPAR5=(5*PAR5), TOTPAR10=(5*PAR5)+(5*PAR10), TOTPAR15=(5*PAR5)+(5*PAR10)+(5*PAR15), TOTPAR30=(5*PAR5)+(5*PAR10)+(5*PAR15)+(15*PAR30), TOTPAR45=(5*PAR5)+(5*PAR10)+(5*PAR15)+(15*PAR30)+(15*PAR45), TOTPAR60=(5*PAR5)+(5*PAR10)+(5*PAR15)+(15*PAR30) +(15*PAR45) +(15*PAR60). The minimum and maximum TOTPAR5, TOTPAR10, TOTPAR15, TOTPAR30, TOTPAR45, and TOTPAR60 scores were 5 to 25, 10 to 50, 15 to 75, 30 to 150, 45 to 225, and 60 to 300, respectively. A higher score indicates more pain relief. (NCT00538850)
Timeframe: 5 through 60 minutes after dosing for each pain episode
| Intervention | Units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| TOTPAR5 | TOTPAR10 | TOTPAR15 | TOTPAR30 | TOTPAR45 | TOTPAR60 | |
| Fentanyl Sublingual Spray | 8.6 | 19.7 | 32.9 | 78.3 | 126.3 | 176.4 |
| Placebo | 7.6 | 16.7 | 27.1 | 61.0 | 95.5 | 131.2 |
15 reviews available for fentanyl and Cancer-Associated Pain
| Article | Year |
|---|---|
Bibliometric Network Analysis on Rapid-Onset Opioids for Breakthrough Cancer Pain Treatment.
Topics: Analgesics, Opioid; Bibliometrics; Breakthrough Pain; Cancer Pain; Fentanyl; Humans; Neoplasms | 2022 |
Breakthrough cancer pain in the radiotherapy setting: a systematic and critical review.
Topics: Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Fentanyl; Head and Neck Neoplasms; Humans; Neopl | 2023 |
Is pain part of a systemic syndrome in head and neck cancer?
Topics: Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Depression; Exercise; Fatigue; Fentanyl; Head an | 2020 |
Breakthrough cancer pain: review and calls to action to improve its management.
Topics: Algorithms; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Communication; Fentanyl; Humans; Onc | 2020 |
Breakthrough cancer pain in 2020.
Topics: Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Fentanyl; Humans; Neoplasm Metastasis; Pain Mana | 2020 |
Breakthrough Cancer Pain: A Systematic Review of Pharmacologic Management
.
Topics: Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Education, Nursing, Contin | 2017 |
Opioids for cancer pain - an overview of Cochrane reviews.
Topics: Acetaminophen; Administration, Cutaneous; Administration, Oral; Analgesics, Opioid; Buprenorphine; C | 2017 |
Non pharmacological interventions and non-fentanyl pharmacological treatments for breakthrough cancer pain: A systematic and critical review.
Topics: Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Double-Blind Method; Fenta | 2018 |
Treating breakthrough pain in oncology.
Topics: Administration, Buccal; Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Do | 2018 |
Opioid Rotation in Cancer Pain Treatment.
Topics: Analgesics, Opioid; Buprenorphine; Cancer Pain; Chronic Pain; Fentanyl; Germany; Humans; Hydromorpho | 2018 |
Transdermal fentanyl for cancer pain: Trial sequential analysis of 3406 patients from 35 randomized controlled trials.
Topics: Administration, Cutaneous; Analgesics, Opioid; Cancer Pain; Fentanyl; Humans; Neoplasms; Odds Ratio; | 2018 |
[Opioid switch and change of route of administration in cancer patients treated by morphine].
Topics: Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Drug Substitution; Fentany | 2018 |
Intranasal therapy with opioids for children and adolescents with cancer: results from clinical studies.
Topics: Administration, Intranasal; Adolescent; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Child; D | 2019 |
[Opioids for Cancer Pain and its Use under Particular Conditions: A Narrative Review].
Topics: Administration, Oral; Analgesics, Opioid; Buprenorphine; Cancer Pain; Codeine; Deglutition Disorders | 2019 |
A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients.
Topics: Aged; Analgesics, Opioid; Cancer Pain; Confounding Factors, Epidemiologic; Dose-Response Relationshi | 2017 |
19 trials available for fentanyl and Cancer-Associated Pain
| Article | Year |
|---|---|
Efficacy of reconstituted intravenous fentanyl to sublingual solution versus oral morphine syrup for breakthrough pain among patients with chronic gynecologic cancer pain: A randomized, double-blind, placebo-controlled trial.
Topics: Administration, Sublingual; Adolescent; Adult; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; D | 2023 |
Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Cytochrome P-450 CYP3A; Female; Fentanyl; | 2019 |
Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: A randomized controlled trial.
Topics: Administration, Intranasal; Administration, Intravenous; Adult; Aged; Analgesics, Opioid; Cancer Pai | 2020 |
A dose titration study of fentanyl buccal soluble film for breakthrough cancer pain in Taiwan.
Topics: Administration, Buccal; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; Cance | 2019 |
Efficacy and Safety of Fentanyl Citrate Patch, Including a Low-Dose 0.5 mg Formulation, in Opioid-Naïve Patients with Cancer Pain.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analgesics, Opioid; Ca | 2020 |
Efficacy, safety, and tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; C | 2021 |
A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Aged, 80 and over; Analgesics, Opioid; Bupren | 2017 |
[Fentanyl buccal tablets in the treatment of breakthrough cancer pain. German cohort of a pan-European multicentre study].
Topics: Administration, Buccal; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; Cance | 2018 |
Proportional dose of rapid-onset opioid in breakthrough cancer pain management: An open-label, multicenter study.
Topics: Administration, Buccal; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Dose-Respon | 2018 |
Effect of Opioid Exposure on Efficacy and Tolerability of Sublingual Fentanyl and Subcutaneous Morphine for Severe Cancer Pain Episodes. Secondary Analysis From a Double-Blind Double-Dummy, Randomized Trial.
Topics: Administration, Cutaneous; Administration, Sublingual; Aged; Analgesics, Opioid; Cancer Pain; Dose-R | 2019 |
Comparison of the Quality of Life of Cancer Patients with Pain Treated with Oral Controlled-Release Morphine and Oxycodone and Transdermal Buprenorphine and Fentanyl.
Topics: Analgesics, Opioid; Buprenorphine; Cancer Pain; Delayed-Action Preparations; Female; Fentanyl; Human | 2019 |
Breakthrough pain in patients with head & neck cancer. A secondary analysis of IOPS MS study.
Topics: Administration, Intranasal; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthr | 2019 |
Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain.
Topics: Administration, Sublingual; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Double- | 2016 |
Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV 'real life' trial on the variability of response to opioids.
Topics: Adult; Aged; Analgesics, Opioid; Cancer Pain; Drug-Related Side Effects and Adverse Reactions; Femal | 2016 |
Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV 'real life' trial on the variability of response to opioids.
Topics: Adult; Aged; Analgesics, Opioid; Cancer Pain; Drug-Related Side Effects and Adverse Reactions; Femal | 2016 |
Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV 'real life' trial on the variability of response to opioids.
Topics: Adult; Aged; Analgesics, Opioid; Cancer Pain; Drug-Related Side Effects and Adverse Reactions; Femal | 2016 |
Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV 'real life' trial on the variability of response to opioids.
Topics: Adult; Aged; Analgesics, Opioid; Cancer Pain; Drug-Related Side Effects and Adverse Reactions; Femal | 2016 |
Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl.
Topics: Administration, Cutaneous; Administration, Sublingual; Adult; Aged; Aged, 80 and over; Analgesics, O | 2016 |
[Dose-finding for treatment with a transdermal fentanyl patch : Titration with oral transmucosal fentanyl citrate and morphine sulfate].
Topics: Administration, Buccal; Administration, Cutaneous; Adult; Aged; Cancer Pain; Chronic Pain; Dose-Resp | 2016 |
Fentanyl Pectin Nasal Spray Versus Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Comparative Study.
Topics: Administration, Oral; Analgesics; Breakthrough Pain; Cancer Pain; Cross-Over Studies; Female; Fentan | 2016 |
Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer.
Topics: Adult; Aged; Analgesics, Opioid; Cancer Pain; Female; Fentanyl; Head and Neck Neoplasms; Humans; Mal | 2016 |
Fentanyl Sublingual Tablets Versus Subcutaneous Morphine for the Management of Severe Cancer Pain Episodes in Patients Receiving Opioid Treatment: A Double-Blind, Randomized, Noninferiority Trial.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Double- | 2017 |
53 other studies available for fentanyl and Cancer-Associated Pain
| Article | Year |
|---|---|
Tapentadol in Cancer Patients with Neuropathic Pain: A Comparison of Methadone, Oxycodone, Fentanyl, and Hydromorphone.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Dose-Response Relationship, Drug; F | 2021 |
An Open-Label Study of the Pharmacokinetics and Tolerability of Once-a-Day Fentanyl Citrate Patch in Japanese Pediatric and Adolescent Patients with Cancer Pain.
Topics: Administration, Cutaneous; Adolescent; Analgesics, Opioid; Cancer Pain; Child; Child, Preschool; Fen | 2021 |
Low-dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain in palliative care.
Topics: Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Fentanyl; Humans; Neoplasms; Palliative Care; Pr | 2022 |
[For the Clinical Use-Clinical Guidelines for Pharmacological Management of Cancer Pain 2020].
Topics: Analgesics, Opioid; Cancer Pain; Fentanyl; Humans; Morphine; Neoplasms; Tramadol | 2022 |
Effect of Transdermal Fentanyl Patch Combined with Enhanced Recovery after Surgery on the Curative Effect and Analgesic Effect of Liver Cancer.
Topics: Administration, Cutaneous; Analgesics, Opioid; Cancer Pain; Enhanced Recovery After Surgery; Fentany | 2022 |
Differences in Fentanyl Requirements in Terminally Ill Cancer Patients.
Topics: Analgesics, Opioid; Cancer Pain; Female; Fentanyl; Humans; Male; Neoplasms; Pancreatic Neoplasms; Re | 2023 |
Differences in Fentanyl Requirements in Terminally Ill Cancer Patients.
Topics: Analgesics, Opioid; Cancer Pain; Female; Fentanyl; Humans; Male; Neoplasms; Pancreatic Neoplasms; Re | 2023 |
Differences in Fentanyl Requirements in Terminally Ill Cancer Patients.
Topics: Analgesics, Opioid; Cancer Pain; Female; Fentanyl; Humans; Male; Neoplasms; Pancreatic Neoplasms; Re | 2023 |
Differences in Fentanyl Requirements in Terminally Ill Cancer Patients.
Topics: Analgesics, Opioid; Cancer Pain; Female; Fentanyl; Humans; Male; Neoplasms; Pancreatic Neoplasms; Re | 2023 |
Opioid prescribing and social deprivation: A retrospective analysis of prescribing for CNCP in Liverpool CCG.
Topics: Analgesics, Opioid; Cancer Pain; Chronic Pain; Female; Fentanyl; Humans; Male; Morphine; Practice Pa | 2023 |
Comparison of Analgesic Efficacy and Safety of Low-Dose Transdermal Fentanyl and Oral Oxycodone in Opioid-Naïve Patients with Cancer Pain.
Topics: Administration, Cutaneous; Analgesics; Analgesics, Opioid; Cancer Pain; Fentanyl; Humans; Neoplasms; | 2023 |
Prevalence of opioid-induced adverse events across opioids commonly used for analgesic treatment in Japan: a multicenter prospective longitudinal study.
Topics: Analgesics, Opioid; Cancer Pain; Constipation; Delirium; Fentanyl; Humans; Hydromorphone; Japan; Lon | 2023 |
Does transdermal fentanyl work in patients with low BMI? Patient-reported outcomes of pain and percent pain relief in cancer patients on transdermal fentanyl.
Topics: Administration, Cutaneous; Analgesics, Opioid; Body Mass Index; Cancer Pain; Female; Fentanyl; Human | 2019 |
Risk Factors for Poor Pain Control after Opioid Switching from Oxycodone Tablet to Fentanyl Patch.
Topics: Aged; Analgesics, Opioid; Cancer Pain; Dose-Response Relationship, Drug; Drug Interactions; Drug Sub | 2019 |
Effectiveness of Risk Minimization Measures for Fentanyl Buccal Tablet (FENTORA) in Canada: A Mixed-Methods Evaluation Using Surveys, Medical Chart Records and Web Surveillance.
Topics: Administration, Buccal; Adolescent; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Canada; Canc | 2020 |
Cancer Cachexia May Hinder Pain Control When Using Fentanyl Patch.
Topics: Aged; Analgesics, Opioid; Cachexia; Cancer Pain; Female; Fentanyl; Humans; Male; Middle Aged; Morphi | 2020 |
[Analysis of Symptoms Relieved in Addition to Pain after Administration of Oxycodone or Morphine to Patients with Advanced Cancer Living at Home].
Topics: Administration, Cutaneous; Analgesics, Opioid; Cancer Pain; Fentanyl; Humans; Morphine; Neoplasms; O | 2020 |
[Use of rapid-onset fentanyl preparations beyond indication : A random questionnaire survey among congress participants and pain physicians].
Topics: Analgesics, Opioid; Cancer Pain; Fentanyl; Humans; Physicians; Surveys and Questionnaires | 2021 |
A low pKa ligand inhibits cancer-associated pain in mice by activating peripheral mu-opioid receptors.
Topics: Analgesics, Opioid; Animals; Bone Neoplasms; Cancer Pain; Cell Line, Tumor; Fentanyl; Hydrogen-Ion C | 2020 |
The role of fentanyl in the treatment of breakthrough cancer pain: Different biotechnologies, different results and different drug costs.
Topics: Administration, Buccal; Administration, Intranasal; Administration, Oral; Analgesics, Opioid; Breakt | 2021 |
Is there a role for pharmacogenetics in the dosing of fentanyl?
Topics: Analgesics, Opioid; Cancer Pain; Fentanyl; Humans; Pharmacogenetics | 2017 |
[A New Therapeutic Approach for Cancer-Related Breakthrough Pain - Focused on Oral Transmucosal Fentanyl].
Topics: Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Fentanyl; Humans; Mouth Mu | 2017 |
Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment.
Topics: Administration, Oral; Administration, Sublingual; Analgesics, Opioid; Breakthrough Pain; Cancer Pain | 2017 |
Breakthrough Pain Management with Sublingual Fentanyl Tablets in Patients with Cancer: Age Subgroup Analysis of a Multicenter Prospective Study.
Topics: Administration, Sublingual; Age Factors; Aged; Analgesics, Opioid; Anxiety; Breakthrough Pain; Cance | 2017 |
Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS.
Topics: Administration, Buccal; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; Cance | 2018 |
Transmucosal fentanyl for severe cancer pain: Nasal mucosa superior to oral mucosa?
Topics: Breakthrough Pain; Cancer Pain; Fentanyl; Humans; Mouth Mucosa; Nasal Mucosa | 2016 |
Characteristics and Treatment of Breakthrought Pain (BTcP) in Palliative Care.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesia, Patient-Controlled; Analgesics, Non-Narcot | 2017 |
Bioanalytical methods for the quantification of hydromorphone, fentanyl, norfentanyl, morphine, morphine-3ß-glucuronide and morphine-6ß-glucuronide in human plasma.
Topics: Acetonitriles; Analgesics, Opioid; Calibration; Cancer Pain; Chromatography, High Pressure Liquid; D | 2018 |
The use of rapid onset fentanyl in children and young people for breakthrough cancer pain.
Topics: Administration, Oral; Adolescent; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Child; Child, | 2017 |
[Transmucosal fentanyl administration: sublingual, buccal, nasal - all the same? Treatment of breakthrough cancer pain].
Topics: Administration, Mucosal; Administration, Sublingual; Analgesics, Opioid; Breakthrough Pain; Cancer P | 2017 |
Effects of smoking and body mass index on the exposure of fentanyl in patients with cancer.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Body Mass Index; Cancer Pain; Cohort Studies; F | 2018 |
Analgesic effects of systemic fentanyl on cancer pain are mediated by not only central but also peripheral opioid receptors in mice.
Topics: Action Potentials; Analgesics, Opioid; Animals; Cancer Pain; Cell Line, Tumor; Disease Models, Anima | 2018 |
Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer.
Topics: Administration, Buccal; Administration, Intranasal; Aged; Aged, 80 and over; Analgesics, Opioid; Bre | 2018 |
The Association between Patient Characteristics and Opioid Treatment Response in Neuropathic and Nociceptive Pain due to Cancer.
Topics: Aged; Analgesics, Opioid; Cancer Pain; Female; Fentanyl; Head and Neck Neoplasms; Humans; Male; Midd | 2019 |
Factors influencing the use of opioids for breakthrough cancer pain: A secondary analysis of the IOPS-MS study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; Canc | 2019 |
Opioid responsiveness of nociceptive versus mixed pain in clinical cancer patients.
Topics: Aged; Analgesics; Analgesics, Opioid; Cancer Pain; Drug Therapy, Combination; Female; Fentanyl; Huma | 2018 |
[Not all pains are the same: breakthrough pain in cancer patients. A case report].
Topics: Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Fentanyl; Humans; Male; Middle Aged; Palliative | 2018 |
Demonstrating Heterogeneity of Treatment Effects Among Patients: An Overlooked but Important Step Toward Precision Medicine.
Topics: Analgesics, Opioid; Cancer Pain; Cross-Over Studies; Double-Blind Method; Fentanyl; Humans; Precisio | 2019 |
Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products.
Topics: Administration, Mucosal; Breakthrough Pain; Cancer Pain; Clinical Competence; Contraindications, Dru | 2019 |
[Breaktrough cancer pain in metastatic prostate adenocarcinoma: a case report.]
Topics: Adenocarcinoma; Administration, Sublingual; Analgesics, Opioid; Bone Neoplasms; Breakthrough Pain; C | 2019 |
Expert consensus on the management of breakthrough cancer pain in older patients. A Delphi study.
Topics: Administration, Mucosal; Aged; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Central Nervous S | 2019 |
Effectiveness of fentanyl pectin nasal citrate in controlling episodes of breakthrough cancer pain triggered by routine radiotherapy procedures.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Female; Fentanyl | 2019 |
Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets.
Topics: Administration, Sublingual; Aged; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Female; Fentan | 2019 |
Practices and perceptions regarding intravenous opioid infusion and cancer pain management.
Topics: Adult; Analgesics, Opioid; Cancer Pain; Clinical Competence; Cross-Sectional Studies; Female; Fentan | 2019 |
Medical Use of Long-term Extended-release Opioid Analgesics in Commercially Insured Adults in the United States.
Topics: Adult; Aged; Analgesics, Opioid; Arthritis; Back Pain; Cancer Pain; Chronic Pain; Delayed-Action Pre | 2020 |
Indication of Adequate Transdermal Fentanyl Dose in Opioid Switching From Oral Oxycodone in Patients With Cancer.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Analge | 2016 |
Exposure to Fentanyl After Transdermal Patch Administration for Cancer Pain Management.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Female; | 2016 |
The Influence of Low Salivary Flow Rates on the Absorption of a Sublingual Fentanyl Citrate Formulation for Breakthrough Cancer Pain.
Topics: Administration, Sublingual; Aged; Analgesics, Opioid; Autonomic Agents; Breakthrough Pain; Cancer Pa | 2016 |
Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Female; | 2016 |
The Opioid Rotation Ratio From Transdermal Fentanyl to "Strong" Opioids in Patients With Cancer Pain.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Female; | 2016 |
Re: The Influence of Low Salivary Flow Rates on Sublingual Fentanyl Absorption for Breakthrough Cancer Pain.
Topics: Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Fentanyl; Humans; Neoplasms | 2016 |
Incidence of Delirium Among Patients Having Cancer Injected With Different Opioids for the First Time.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Delirium; Drug-Related Side Effects | 2017 |
Relationship between the plasma fentanyl and serum 4β-hydroxycholesterol based on CYP3A5 genotype and gender in patients with cancer pain.
Topics: Aged; Analgesics, Opioid; Cancer Pain; Cytochrome P-450 CYP3A; Female; Fentanyl; Genotype; Humans; H | 2016 |
Reply-Letter to the Editor: What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion.
Topics: Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Expert Testimony; Fentanyl; Humans; Neoplasms | 2016 |
Dose and Duration of Opioid Use in Patients with Cancer and Noncancer Pain at an Outpatient Hospital Setting in Malaysia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Cross-Sectional Studies | 2017 |
Opioid manufacturer bribed doctors to prescribe fentanyl inappropriately, US says.
Topics: Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Crime; Drug Industry; Fentanyl; Humans; Malpract | 2016 |